PCSK9-targeting antisense inhibitor (OliPass)

N/A

Report date: 2025/03/20 15:26:44
NME

Base Information

Drug NamePCSK9-targeting antisense inhibitor (OliPass)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHypercholesterolemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOlipass Co
China Registration ClassN/A

Develop Information

Active CompaniesOlipass Co
Inactive CompaniesN/A
Active IndicationsHypercholesterolemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A